Recursion Pharmaceuticals reports fourth-quarter and full-year 2025 results Wednesday before the market opens, with investors scrutinizing whether the AI-driven biotech can translate its massive data ...
Salt Lake City, Utah, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced that on February 6, ...
Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...
Hosted on MSN
If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today
Recursion Pharmaceuticals has significantly lagged the market since its 2021 IPO. The company's potentially revolutionary approach has yet to produce results. The stock's upside is enormous if ...
The company isn't the only developer of a drug for FAP, a rare genetic disease. A rival just reported that its own FAP treatment is advancing to late-stage testing. This was largely due to news from a ...
The de-risking event relates to the acquisition of the 50% interest in an ENPP1 inhibitor program (REV102) that it didn't own from Rallybio (NASDAQ: RLYB). REV102 is being developed to treat ...
– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – Rallybio Corporation (Nasdaq: RLYB), a ...
Community driven content discussing all aspects of software development from DevOps to design patterns. Good programmers need to create code that efficiently solves problems, using various methods. A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results